Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
NORINYL 1+35 21-DAY is an oral contraceptive tablet combining norethindrone (1 mg) and ethinyl estradiol (35 mcg) in a 21-day regimen. It prevents pregnancy through hormonal suppression of ovulation and alters cervical mucus and endometrial conditions to reduce fertility. This product represents a foundational birth control option in the combined oral contraceptive class.
As a legacy oral contraceptive approaching loss of exclusivity, the brand faces moderate competitive pressure (30) and likely operates with a lean team focused on retention and managed decline.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NORINYL 1+35 21-DAY offers limited career growth opportunity given the product's LOE-approaching status and zero linked job postings. Roles are primarily focused on defending market position, managing reimbursement pressure, and supporting existing customers rather than driving innovation or expansion.
Worked on NORINYL 1+35 21-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.